March 2022

COVER

SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies

Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.

FEATURES

SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies

Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.

DRUG DEVELOPMENT - The Promise of Cutting-Edge Microbiome-Based Therapeutics

Andrew Thomson, Brian Carpenter, and Robert Broadnax focus on how developers must strategically address and overcome specific challenges to successfully drive development and eventual adoption of microbiome-based therapies.

NASAL DELIVERY - Improving Nasal Drug Delivery With Permeation Enhancing Technology

Stuart Madden, PhD, focuses on the use of alkylsaccharides as absorption enhancers for nasal delivery of a wide range of drug types.

FORMULATION DEVELOPMENT - Impact of Excipients & Manufacturing Process on Solubility-Enhanced Ritonavir Tablet Size & Weight Reduction

Gayatri Khanvilkar, MPharm, Ajit Bhagat, and Tejas Gunjikar, PhD, investigate bulking agents and disintegrants to develop efficacious Rotonavir tablets with improved in vitro release.

DATA STRATEGIES - As We Shift Toward Biologics, We Also Need to Shift Toward Smarter Data Management

Christian Marcazzo explains how adopting a new kind of data strategy might be disruptive to the expectation of how biologics development is carried out — but it may also be transformational.

MARKET LANDSCAPE - The Future of Cancer Care Post-Pandemic: What Doctors, Patients, and the Healthcare Industry at Large Should Expect

Angelos Stergiou, PhD, explains how the COVID-19 pandemic saw failures in the healthcare delivery system not only in general medicine, but also specifically in oncology. At the same time, several opportunities came to light during such a difficult, frightening moment, bringing a number of large- and small-scale innovations forth.

EXECUTIVE INTERVIEW - Kytosan USA, Inc.: Blazing a Trail in Chitosan Manufacturing in the United States

Dr. Joseph F. Bristow, Chief Technology Officer for Kytosan USA, discusses chitosan and its impact on the pharmaceutical industry, as well as Kytosan USA’s production plans.

GENE EDITING TECHNOLOGY - Harnessing a Cell’s Natural DNA Repair Process to Develop Medicines With Higher Levels of Precision & Durability

Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.

INJECTION TECHNOLOGY - Patient Centricity in Insulin Injection: Using Technology to Improve Self-Administration

David T. Novotny discusses how advances in smart technology have opened up new options for people with diabetes and explores how injection technology has made self-administration of insulin easier, and how it will continue to develop into the future.

CDMO INNOVATION - How a Global CDMO Puts Innovation at the Forefront of its Business Strategy

Kai Vogt, Senior Vice President Corporate Development/Legal/Corporate Compliance/IT, Vetter, explains how a global CDMO puts innovation at the forefront of its business strategy.